US 12,006,318 B2
Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
David J. Arnold, South San Francisco, CA (US); Omar Robles, South San Francisco, CA (US); Duane E. Rudisill, South San Francisco, CA (US); David J. Wustrow, South San Francisco, CA (US); Mikhail Zibinsky, South San Francisco, CA (US); and Sami Karaborni, South San Francisco, CA (US)
Assigned to RAPT Therapeutics, Inc., South San Francisco, CA (US)
Filed by RAPT THERAPEUTICS, INC., South San Francisco, CA (US)
Filed on Nov. 13, 2020, as Appl. No. 17/098,157.
Claims priority of provisional application 62/935,007, filed on Nov. 13, 2019.
Prior Publication US 2021/0139487 A1, May 13, 2021
Int. Cl. C07D 487/04 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); C07K 16/28 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/284 (2013.01); C07K 16/2818 (2013.01); C07B 2200/13 (2013.01)] 46 Claims
 
1. Compound 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-13]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol benzene sulfonate in crystalline form.